Aiyub Patel, MD
Critical Care Medicine · Peoria, ILNPI 1215153077
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.1% of the total across 315 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by AstraZeneca at 29.3% of the total. 2025 is the largest year on record at $1,675, 2.3 times the $738 reported in 2019. Among critical care medicine clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 315 payments — averaging $21.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Jazz Pharmaceuticals Inc.$1K
- Boehringer Ingelheim$674
- Harmony Biosciences LLC$535
- GSK$414
- Mylan Specialty L.p.$220
- plus $2K from 27 others
What the payments were for
- Food & beverage$6,55697%
- Education$1993%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 60 | $1,976 |
| Jazz Pharmaceuticals Inc. | 24 | $1,053 |
| Boehringer Ingelheim | 30 | $674 |
| Harmony Biosciences LLC | 66 | $535 |
| GSK | 28 | $414 |
| Mylan Specialty L.p. | 10 | $220 |
| Insmed, Inc. | 13 | $219 |
| Sanofi | 10 | $217 |
| Regeneron Healthcare Solutions, Inc. | 9 | $184 |
| Intuitive Surgical | 2 | $178 |
| Verona Pharma, Inc. | 2 | $122 |
| Philips North America LLC | 8 | $119 |
| Electromed, Inc. | 16 | $117 |
| Grifols USA, LLC | 5 | $116 |
| Genentech USA, Inc. | 5 | $84 |
| Viatris Specialty LLC | 3 | $80 |
| Shionogi Inc | 2 | $47 |
| Axsome Therapeutics, Inc. | 2 | $44 |
| Actelion Pharmaceuticals US, Inc. | 3 | $42 |
| Advanced Respiratory, Inc | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Amgen | 1 | $32 |
| Bayer | 2 | $30 |
| La Jolla Pharmaceutical Company | 1 | $24 |
| Boston Scientific | 1 | $19 |
| Pulmonx Corporation | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| Veran Medical Technologies, Inc. | 1 | $17 |
| Teleflex LLC | 1 | $16 |
| Circassia Inc. | 1 | $16 |
| Inogen, Inc. | 1 | $15 |
| Vanda Pharmaceuticals Inc. | 1 | $15 |
| Breathe Technologies, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,754 in reported general payments places this provider in the 90th percentile of 281 critical care medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 247 | $307,485 |
| OfevNintedanib Esylate | 15 | $197,670 |
| Pirfenidone | 15 | $151,663 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 17 | $128,075 |
| Incruse ElliptaUmeclidinium Bromide | 185 | $125,613 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 129 | $120,015 |
| Spiriva RespimatTiotropium Bromide | 89 | $102,695 |
| Breo ElliptaFluticasone/Vilanterol | 118 | $94,240 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 47 | $51,393 |
| TezspireTezepelumab-Ekko | 11 | $50,402 |
| SymbicortBudesonide/Formoterol Fumarate | 80 | $40,372 |
| Arnuity ElliptaFluticasone Furoate | 60 | $23,965 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 57 | $18,592 |
| Atrovent HfaIpratropium Bromide | 16 | $16,920 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 383 | $15,994 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $414 | $602,697657 claims |
| Boehringer IngelheimOfev, Spiriva Respimat | $674 | $300,364104 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort | $1,976 | $210,788220 claims |
| Grifols USA, LLCProlastin C | $116 | $128,07517 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 281 critical care medicine providers in Illinois.
Other critical care medicine in Peoria
- Brian ReichardtO Fallon$892K
- Michael CutticaChicago$402K
- Daniel DillingMaywood$208K
- Israel RubinsteinChicago$107K
- John RickelmanQuincy$90K
- Abbas Al-QamariChicago$40K
- Husam NayefPalos Park$24K
- Nureain MirzaOak Lawn$22K
- Edward GarrityBurr Ridge$20K
- Fadi AldaasChicago Ridge$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.